IgA Nephropathy with Macroproteinuria and a GFR of 20-30 ml/min/1.73 m² May Still Benefit from RAS Inhibition

Table 1

Clinical baseline of IgAN patients with stage 4 CKD.

Clinical parameters	Total ()	Stable ()	Progressive ()	value
Clinical findings
Age (y)	40.5 (29.8-49.3)	43.0 (29.5-58.0)	37.0 (29.5-44.5)	0.132
Gender, M (%)	24 (48.0)	16 (55.2)	8 (38.1)	0.233
SBP (mmHg)	135.0 (122.0-147.0)	130.0 (121.0-139.5)	141.0 (125.5-151.0)	0.205
DBP (mmHg)	85.0 (77.8-96.5)	80.0 (76.0-90.0)	93.0 (79.0-100.0)	0.061
MAP (mmHg)	100.2 (95.2-113.0)	98.7 (90.5-103.0)	107.33 (97.2-116.0)	0.080
Hypertension, (%)	30 (60.0)	17 (58.6)	13 (61.9)	0.815
Use of RASi, (%)	25 (50.0)	18 (61.2)	7 (33.3)	0.045
Use of IS, (%)	25 (50.0)	17 (58.6)	8 (38.1)	0.152
Laboratory findings
Hb (g/l)	115.5 (103.8-125.3)	119.0 (110.0-126.5)	107.0 (97.0-120.0)	0.075
eGFR (ml/min/1.73m^2)	25.8 (23.1-26.8)	25.7 (24.1-27.6)	24.3 (19.7-26.6)	0.072
UA (μmol/l)	478.5 (440.5-536.8)	477.0 (450.0-525.5)	480.0 (410.0-574.5)	0.891
iPTH (pg/ml)	76.8 (50.5-136.8)	68.0 (47.5-99.5)	91.4 (58.2-192.3)	0.071
TC (mmol/l)	5.0 (4.1-6.2)	4.8 (4.0-6.1)	6.0 (4.2-6.7)	0.135
TG (mmol/l)	1.8 (1.6-2.4)	1.8 (1.5-2.9)	2.0 (1.6-2.3)	0.340
24 h-UP (g)	2.7 (1.5-4.4)	2.0 (1.5-4.5)	3.0 (1.8-4.4)	0.149
URBC (/HPF)	11.2 (4.7-36.9)	11.5 (4.3-31.1)	10.2 (4.6-42.4)	0.992
Follow-up time (months)	25.5 (12.0-36.0)	36.0 (22.0-36.0)	15.0 (7.5-28.5)	<0.001

IgAN, IgA nephropathy; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; RASi, renin-angiotensin system inhibitor; IS, immunosuppressive agents; Hb, hemoglobin; eGFR, estimated glomerular filtration rate; UA, uric acid; PTH, parathyroid hormone; TC, total cholesterol; TG, triglyceride; 24 h-UP, 24 h urinary protein excretion; URBC, urinary red blood cells.